

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 31 /64</b>		A2	(11) International Publication Number: <b>WO 00/03742</b> (43) International Publication Date: <b>27 January 2000 (27.01.00)</b>
(21) International Application Number: <b>PCT/EP99/05571</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>12 July 1999 (12.07.99)</b>			
(30) Priority Data: <b>98401781.4 15 July 1998 (15.07.98) EP</b>			
(71) Applicant (for all designated States except US): <b>LIPHA [FR/FR]; 34, rue Saint-Romain, F-69008 Lyon (FR).</b>			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): <b>BONHOMME, Yves [FR/FR]; Le Buclay, 21, avenue de la Paix, F-69260 Charbonnières les Bains (FR). NICHOLSON, Geoffrey [GB/GB]; 48 Langdon Avenue, Aylesbury, Buckinghamshire HP21 9UT (GB). CAVE, Gillian [GB/GB]; 26 Hilbre Drive, Ellesmere Port CH65 9JQ (GB). NICHOLSON, Sarah, J. [GB/GB]; 4 Redstone Hill, Helsby, Cheshire WA6 9PE (GB).</b>		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(74) Agent: <b>OBOLENSKY, Michel; Cabinet Lavoix, 2, place d'Estienne d'Orves, F-75441 Paris Cedex 09 (FR).</b>			
(54) Title: <b>SOLID ORAL DOSAGE FORM COMPRISING A COMBINATION OF METFORMIN AND GLIBENCLAMIDE</b>			
(57) Abstract			
<p>The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		



"Solid oral dosage form comprising a combination of metformin and glibenclamide".

The present invention relates to solid oral dosage forms for the treatment of non-insulin dependent diabetes.

Non-insulin dependent diabetes is a metabolic disorder characterized by hyperglycaemia, which occurs due to insulin deficiency, 5 insulin resistance and reduced glucose tolerance.

There are two main groups of oral antidiabetic drugs available: these are the sulphonylureas and the biguanidines. Sulphonylureas act by stimulating insulin release and are thus only effective with some residual pancreatic beta-cell activity, examples of sulphonylureas available are 10 glibenclamide, gliclazide, tolbutamide, glipizide, tolazamide, gliquidone and chlorpropamide. The biguanidines, such as metformin, act by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose, and as they require endogenous insulin they are only effective with some residual pancreatic islet cell activity.

15 The initial treatment of non-insulin dependent diabetes involves diet control and exercise. Only after this has been shown to be inadequate are oral antidiabetic drugs used, and then only to complement the effect of diet and not replace it. Monotherapy with an oral antidiabetic can be an effective treatment for many years. However the efficiency can decrease 20 with time. Due to sulphonylureas and biguanidines having complementary modes of action, combined therapy is now an established form of treatment for non-insulin dependent diabetes.

To improve patient compliance a combined tablet would be an advantage. The present invention relates to solid oral dosage forms 25 comprising a combination of metformin and glibenclamide (also named glyburide).

A combination of metformin with glibenclamide has been disclosed in WO 97/17975 for the treatment of type II diabetes with a defined ratio of the two active ingredients, which is a requirement in order to obtain an 30 optimum therapeutic effect. This prior art defines an optimum therapeutic ratio of metformin hydrochloride to glibenclamide of 100:1, for example 500mg of metformin hydrochloride with 5mg glibenclamide in a single



dosage unit. This ratio allows a range of daily doses, based on increasing the number of tablets taken per day, that avoid poor disease control through underdosing of either ingredient when there is a requirement for co-administration, and avoids hypoglycaemia by overdosing of either 5 component when so co-administered. Assurance of performance in clinical use, which will derive from having a product exhibiting appropriate bioavailability of the glibenclamide component, is a key requirement for physicians wishing to treat patients with a combination formulation. Appropriate bioavailability implies that 5mg of glibenclamide formulated 10 into a combination tablet with metformin is absorbed to an acceptably similar extent, and at a comparable rate, to glibenclamide dosed as a single entity formulation of the same strength when dosed concurrently with a single entity formulation of metformin.

This prior art does not teach how to formulate a combination 15 product of metformin with glibenclamide so as to assure appropriate bioavailability of the glibenclamide component. There is no issue in this respect in the case of metformin hydrochloride on account of its high water solubility and therefore the bioavailability of metformin from combination formulations will not be discussed further. It is however a very 20 important aspect to consider for glibenclamide as this is a poorly soluble drug substance (solubility is 0.1mg/ml in water at 25°C – practically insoluble as defined by the USP).

As such, its rate of solution after administration of a dosage form will influence the rate and extent of entry of the drug into the bloodstream 25 (bioavailability). The control of the rate and extent of entry into the bloodstream is important for appropriate therapeutic effect.

Hence, the reference discloses a suitable ratio of the two active ingredients in a single dosage form, in order to model how the two individual ingredients might be desirably co-administered (based on how 30 they would be dosed according to usual practice associated with currently available single entity formulations), it does not teach how to assure that such a combination formulation will perform in terms of bioavailability of



glibenclamide. This bioavailability should be as similar as possible to when the relevant doses of the two single entity formulations are co-administered.

In addition, when a combination tablet using standard galenic procedures is proceeded with standard generic glibenclamide in the combination tablet, a reduced bioavailability in comparison to the co-prescribed situation was apparent.

It has now been found using in-vitro and in-vivo testing that the reduced bioavailability is related to the particle size and the particle size distribution of the glibenclamide. It has been found that particles which are too small result in high glibenclamide blood levels with consequent risk of hypoglycaemia and particles which are too large cannot dissolve sufficiently rapidly to give comparable bioavailability with the co-prescribed situation. It is therefore necessary to have a closely defined particle size distribution of the glibenclamide in the combination form.

The selection of a specific size fraction of glibenclamide enables the production of a solid oral dosage form comprising a combination of metformin and glibenclamide, and in particular a tablet, exhibiting glibenclamide bioavailability comparable to the bioavailability obtained with the separated administration of metformin and glibenclamide, when judged by the area under the curve of the in-vivo analysis.

The present invention provides in particular a tablet comprising a combination of metformin and glibenclamide, exhibiting a comparable glibenclamide bioavailability to the co-administered tablets.

In a first embodiment, the solid oral form such as a tablet, according to the invention, contains a combination of glibenclamide and metformin in which the size of the glibenclamide is such that at most 10% of the particles are less than 2  $\mu\text{m}$  and at most 10% of the particles are greater than 60  $\mu\text{m}$ . Preferably, the size of the glibenclamide is such that at most 10% of the particles are less than 3  $\mu\text{m}$  and at most 10% of the particles

are greater than 40  $\mu\text{m}$ . This specific particle size range of glibenclamide may be obtained by sieving or air jet milling.

In a second embodiment, the solid oral dosage form comprises a combination of metformin and glibenclamide in which the size of 5 glibenclamide is such that at most 25 % of the particles are less than 11  $\mu\text{m}$  and at most 25 % of the particles are greater than 46  $\mu\text{m}$ .

Preferably, 50 % of particles are less than 23  $\mu\text{m}$ .

Metformin may be used as a salt of metformin, such as hydrochloride, fumarate, hydrobromide, p-chlorophenoxy acetate or 10 embonate. The weight ratio of metformin salt to glibenclamide should preferably be between 50/1 to 250/1.

The preferred compositions for the oral dosage form is provided in the table below, with ranges on components being provided:

15

	Amount of ingredient, mg per tablet		
Product identity	500/5	500/2,5	250/1.25
Ingredient			
Metformin hydrochloride	500.0	500.0	250.0
Glibenclamide	5.00	2.50	1.25
Croscarmellose sodium	6.0 – 30.0	6.0 – 30.0	3.0 – 15.0
Microcrystalline cellulose	30.0 – 120.0	30.0 – 120.0	15.0 – 60.0
Polyvinyl pyrrolidone	6.0 – 36.0	6.0 – 36.0	3.0 – 18.0
Magnesium stearate	0.6 – 15.0	0.6 – 15.0	0.3 – 7.5
Film coat*	9.0 – 24.0	9.0 – 24.0	4.5 – 12.0

\* a commercially-available film coat composition is used, such as Opadry (Colorcon, UK).

The especially preferred compositions are as follows:

Product identity	Amount of ingredient, mg per tablet		
	500/5	500/2,5	250/1.25
Ingredient			
Metformin hydrochloride	500.0	500.0	250.0
Glibenclamide	5.00	2.50	1.25
Croscarmellose sodium	14.0	14.0	7.0
Microcrystalline cellulose	54.0	56.5	28.25
Polyvinyl pyrrolidone	20.0	20.0	10.0
Magnesium stearate	1.2 – 12.0	1.2 – 12.0	0.6 – 6.0
Film coat*	9.0 – 24.0	9.0 – 24.0	4.5 – 12.0

\* a commercially-available film coat composition is used, such as Opadry (Colorcon, UK).

The tablet according to the present invention may be obtained by a process comprising:

- a) forming granules by wet granulation of a mixture of metformin and glibenclamide;
- b) blending the granules with a tabletting aid and diluent, and
- c) tabletting the blend thus obtained into tablets.

Advantageously the mixture used for forming the granules comprises a granulating binder. This granulating binder is in particular a polyvinylpyrrolidone such as for example, a polyvinylpyrrolidone having a molecular weight of 45 000. The polyvinylpyrrolidone may be used in a proportion of 2 to 4% by weight with respect to the final tablet.

After the granulating step the granules may be sieved and dried.

The granules are then blended with a diluent and tabletting aid. The diluent may be any material usually used for making tablets, such as microcrystalline cellulose. The tabletting aid may be any material usually for making tablets, such as magnesium stearate.



The tablets thus obtained may then be coated with a hydrophilic cellulose polymer and talc. The hydrophilic cellulose polymer may be 2-hydroxypropyl methylcellulose.

The following examples and tests illustrate the present invention.

5

#### Example 1

A tablet of metformin/glibenclamide has been prepared as follows:

66.6 g of polyvinylpyrrolidone are mixed with 246 g of purified water  
10 with a stirrer. 1500 g metformin hydrochloride, 7.5 g of glibenclamide (with a 10 to 90% size range between 2 to 60  $\mu\text{m}$ ), 42 g croscarmellose sodium and 284.4 g of microcrystalline cellulose are mixed in a granulator. The polyvinylpyrrolidone solution is added to the granulator and the wet mass is granulated. The granules are extruded through a 1 mm mesh.  
15 The granules are emptied into a preheated fluidised bed dryer and the granules are dried. 97.5 g of microcrystalline cellulose is mixed into the granules using a tumbling mixer. 12 g of magnesium stearate is added to the tumbling mixer and mix. The granule mix is tabletted using a suitable tablet press. The tablets are coated with a 2% hydroxypropyl  
20 methylcellulose coat in a coating machine.

#### Example 2

A tablet of metformin/glibenclamide has been prepared as follows:

25 5.83 g of glibenclamide (with a 10 to 90% size range between 2 to 60  $\mu\text{m}$ ), are preblended with 32.67 g of croscarmellose sodium. 46.67 g of polyvinylpyrrolidone are mixed with 93.33 g of purified water with a stirrer. The glibenclamide-croscarmellose sodium blend is mixed with 1166.6 g of metformin hydrochloride in a granulator. The polyvinylpyrrolidone solution  
30 is added to the granulator and the wet mass is granulated. The granules are emptied into a preheated fluidised bed dryer and the granules are



dried. The particle size of the granules is reduced by passing through a 1 mm mesh. 131.83 g of microcrystalline cellulose are mixed into the granules in the granulator. 16.3 g of magnesium stearate are added to the granulator and mixed. The granule mix is tabletted using a suitable tablet press. The tablets are coated with a 2% hydroxypropyl methylcellulose coat in a coating machine.

### Test 1

10 In-vivo bioavailability tests were performed with tablets prepared as disclosed in example 2, using two batches of glibenclamide. The two batches have the following 10 to 90% particle size range:

batch A: 3.47-38.08  $\mu$ m

batch B: 15.63-91.6  $\mu$ m.

15 The distribution of the particle size of batches A and B are illustrated in figure 1.

The two batches of tablets were administered to healthy patients in comparison to co-administered glibenclamide (marketed under the trade name Daonil) and metformin hydrochloride (16 patients for each group).

20 The comparative concentrations of glibenclamide in a tablet comprising a combination of metformin and respectively the batch A and the batch B of glibenclamide and with the co-administration are shown respectively in figures 2 and 3.

The area under the curve (AUC) are the following:

25

	AUC (ng/ml/h)
combination with batch A	790.5
combination with batch B	353.0
co-administration	869.3

30

It appears that with the combination according to the invention with batch A the AUC is substantially the same as in the case of co-administration, whereas with the combination with batch B the AUC is more clearly different.

5

### Test 2

Careful examination of blood levels of glibenclamide in humans following administration of a series of tablet formulations of metformin hydrochloride combined with glibenclamide (identified as formulations Combo 1, 2, 3 and 4), where the formulation are identical save for the particle size characteristics of the glibenclamide used, compared with commercially available reference formulations of metformin hydrochloride (Glucophage™, Bristol-Myers Squibb) and glibenclamide (Micronase™, Upjohn) dosed together, allowed definition of particle characteristics for glibenclamide that would assure appropriate bioavailability of the glibenclamide component from the combination formulation. This means that disease control when patients are first treated with such a combination formulation will be predictable, based on prior physician knowledge of treatments employing either single drug.

Alternatively, if patients have undergone prior stabilisation of their disease by adding treatment with a commercial product like Micronase™ to existing treatment with Glucophage™ (or vice versa), then the switch over to a more convenient treatment employing the combination in a single tablet (and where the appropriate bioavailability of the glyburide component is assured) will result in the desired level of disease control being maintained.

Data from the studies with metformin hydrochloride/glibenclamide tablets formulated with glibenclamide of different particle size characteristics allowed the development of a correlation between drug particle size and the *in vivo* performance. The properties of the lots of

glyburide used in the series of combination tablets employed are shown in the table below:

Tablet batch	glibenclamide particle size (microns)		
	25 % undersize	50 % undersize	75 % undersize
Combo 1	15	33	62
Combo 2	28	58	88
Combo 3	10	25	52
Combo 4	6	11	19

5 When four compositionally-identical individual batches of tablets of metformin hydrochloride-glyburide 500/2.5mg were prepared using each of these lots of glibenclamide and dosed to humans, the following pharmacokinetic parameters were found on analysis of the glibenclamide plasma concentration-time curves:

10

Tablet batch	Pharmacokinetic parameters glibenclamide			
	Cmax (ng/ml, geo. mean)	AUC (ng/ml/hr, geo. mean)	Cmax (ng/ml, arith. mean)	AUC (ng/ml/hr, arith. mean)
Combo 1	71	478	76	493
Combo 2	52	345	54	339
Combo 3	64	513	67	531
Combo 4	88	642	93	716

15 A reasonable correlation can be obtained between particle size and the maximum attained geometric mean glibenclamide plasma concentration, Cmax, and also with the geometric mean area under the glibenclamide plasma concentration-time curve, AUC.

From these correlations, projected limits on particle size for glyburide that would give predicted Cmax and AUC values  $\pm$  25 % of a

mean value for batches of the reference glibenclamide formulation, Micronase™ utilised in the *in vivo* studies become:

	<u>25% undersize limits</u>	<u>50% undersize limits</u>	<u>75% undersize limits</u>
Cmax	<0-18 microns	<0-37 microns	<0-63 microns
AUC	<0-11 microns	<0-25 microns	<0-46 microns

5 Accommodating both Cmax and AUC requirements, the projected limits then become:

	<u>25% undersize limits</u>	<u>50% undersize limits</u>	<u>75% undersize limits</u>
	≤ 11 microns	≤ 23 microns	≤ 46 microns

10 Glibenclamide having these particle size characteristics have powder surface area values in the range  $1.7$  to  $2.2 \text{ m}^2\text{g}^{-1}$  as determined by nitrogen adsorption. Therefore material of these properties when formulated as described in this work is distinct from the material disclosed in US 3 979 520 which required glibenclamide of powder surface area in excess of  $3\text{m}^2\text{g}^{-1}$  (preferably 5 to  $10 \text{ m}^2\text{g}^{-1}$ ) to yield appropriate 15 glibenclamide bioavailability. The glibenclamide of particle size properties detailed in this work, when formulated as described here produces appropriate glibenclamide bioavailability in humans as described in the next test.

20 Test 3

A batch of metformin hydrochloride-glibenclamide tablets 500/5mg was prepared as follows. Glibenclamide (1.0kg) with the above defined size was tumble mixed with 2.8kg of croscarmellose sodium and this 25 mixture was then blended in a high shear mixer with metformin hydrochloride (100kg) to which 0.5% by weight of magnesium stearate had been added.



This dry mix was wet granulated in a high shear mixer with 12.1kg of an aqueous solution of povidone (containing 4kg of povidone). The wet granules were dried in a fluid bed drier at 60°C to a defined moisture content. The dried (loss on drying 2-3% w/w) granules were size reduced

5 in a oscillator (1.0mm screen aperture) then tumble mixed with 10.8kg of microcrystalline cellulose, followed by mixing with 0.9kg of the tablet lubricant magnesium stearate. The lubricated granules were compressed using 16mm x 8mm capsule shaped tooling and the tablet cores were film coated (weight gain approximately 2% w/w) with the proprietary film coat

10 material Opadry 32920 to yield the final yellow, capsule-shaped tablets. In a human pharmacokinetic study volunteer either were dosed with one of these tablets or with a treatment being one 500mg Glucophage™ tablet plus one 5mg Micronase™ tablet co-administered. Glibenclamide plasma levels following dosing were analysed and the following pharmacokinetic

15 were found for this component:

Treatment	Parameter	Mean	Adjusted geometric mean	Ratio of means (Point estimate)
Combination Tablet 500/5	Cmax	122	116	1.14
	AUC (O-T)	859	831	1.07
Glucophage + Micronase	Cmax	113	101	-
	AUC (O-T)	842	780	-

Glibenclamide bioavailability from the combination tablet is comparable to that from the reference glibenclamide formulation,

20 Micronase™. This would thus allow patients to conveniently take one tablet of the combination product instead of two tablets of existing therapies together, without concern that low glibenclamide blood levels would result, which might occur with prior art formulations and lead to loss of control of disease.

Example 3

Instead of compressing into tablet granulation as prepared for test 3  
5 was filled into size 00 capsules to either provide for metformin hydrochloride/glibenclamide 500mg/5mg product or the 500mg/2.5mg product. Granulation was filled into size 1 capsules to provide the 250mg/2.5mg product.

These capsule exhibited acceptable physical properties and  
10 provide an alternative to the tablets. Formulations as described in WO 97/17975 could not be filled in capsules of a size acceptable to most patients because of the larger amount of excipients employed the formulations they described.



CLAIMS

1. A solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the 5 glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.
2. A solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of the glibenclamide is such that at 10 most 10% of the particles are less than 2  $\mu\text{m}$  and at most 10% of the particles are greater than 60  $\mu\text{m}$ .
3. A solid oral dosage form as claimed in claim 2 in which the size of the glibenclamide is such that at most 10% of the particles are less than 3  $\mu\text{m}$  at most 10% of the particles are greater than 40  $\mu\text{m}$ . 15
4. A solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that at most 25 % of the particles are less than 11  $\mu\text{m}$  and at most 25 % of the particles are greater than 46  $\mu\text{m}$ .
5. A solid oral dosage form in which 50 % of particles are less than 20 23  $\mu\text{m}$ .
6. A solid oral dosage form as claimed in any one of claims 1 to 4 in which metformin is present as metformin salt and the weight ratio of metformin salt to glibenclamide is 50/1 to 250/1.
7. A solid oral dosage form as claimed in any one of claims 1 to 6 25 which is a tablet.
8. A tablet as claimed in claim 7 which is obtained by a process comprising:
  - a) forming granules by wet granulation of a mixture of metformin and glibenclamide;
  - 30 b) blending the granules with a tabletting aid
  - c) tabletting the blend thus obtained into tablets.

1/3




FIG.1

2/3




FIG. 2

3/3




FIG. 3

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 31/64 // (A61K 31/64, 31:155)</b>		A3	(11) International Publication Number: <b>WO 00/03742</b> (43) International Publication Date: <b>27 January 2000 (27.01.00)</b>
(21) International Application Number: <b>PCT/EP99/05571</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>12 July 1999 (12.07.99)</b>		(30) Priority Data: <b>98401781.4 15 July 1998 (15.07.98) EP</b>	
(71) Applicant (for all designated States except US): <b>LIPHA [FR/FR]; 34, rue Saint-Romain, F-69008 Lyon (FR).</b>		(72) Inventors; and	
(75) Inventors/Applicants (for US only): <b>BONHOMME, Yves [FR/FR]; Le Buclay, 21, avenue de la Paix, F-69260 Charbonnières les Bains (FR). NICHOLSON, Geoffrey [GB/GB]; 48 Langdon Avenue, Aylesbury, Buckinghamshire HP21 9UT (GB). CAVE, Gillian [GB/GB]; 26 Hilbre Drive, Ellesmere Port CH65 9JQ (GB). NICHOLSON, Sarah, J. [GB/GB]; 4 Redstone Hill, Helsby, Cheshire WA6 9PE (GB).</b>		(88) Date of publication of the international search report: <b>20 April 2000 (20.04.00)</b>	
(74) Agent: <b>OBOLENSKY, Michel; Cabinet Lavoix, 2, place d'Estienne d'Orves, F-75441 Paris Cedex 09 (FR).</b>		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: <b>SOLID ORAL DOSAGE FORM COMPRISING A COMBINATION OF METFORMIN AND GLIBENCLAMIDE</b>			
(57) Abstract			
<p>The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 99/05571

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/64 // (A61K31/64, 31:155)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 17975 A (GENTILI IST SPA ; BARELLI GIULIO (IT); REGIS MASSIMO DE (IT)) 22 May 1997 (1997-05-22) claims	1-4
Y	US 4 060 634 A (ROTHE WERNER ET AL) 29 November 1977 (1977-11-29) column 4, line 32 - line 49	1-4

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

15 February 2000

Date of mailing of the International search report

23/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epnl,  
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C



## INTERNATIONAL SEARCH REPORT

## Information on patent family members

International Application No

PCT/EP 99/05571

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9717975	A 22-05-1997	IT 9152337 A		14-05-1997
		AU 7566896 A		05-06-1997
		BR 9611448 A		23-03-1999
		CA 2237571 A		22-05-1997
		EP 0869796 A		14-10-1998
		US 5922769 A		13-07-1999
US 4060634	A 29-11-1977	DE 2348334 A		27-03-1975
		AT 330954 B		26-07-1976
		AT 762374 A		15-10-1975
		AU 7365374 A		01-04-1976
		BE 820254 A		24-03-1975
		CA 1029661 A		18-04-1978
		FI 275574 A,B,		27-03-1975
		FR 2244455 A		18-04-1975
		GB 1420907 A		14-01-1976
		JP 1089246 C		23-03-1982
		JP 50058216 A		21-05-1975
		JP 56032967 B		31-07-1981
		NL 7412393 A,B,		01-04-1975
		SE 402210 B		26-06-1978
		SE 7412044 A		27-03-1975
		US 3979520 A		07-09-1976
		ZA 7405967 A		26-11-1975